244 related articles for article (PubMed ID: 22315352)
1. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.
John LB; Howland LJ; Flynn JK; West AC; Devaud C; Duong CP; Stewart TJ; Westwood JA; Guo ZS; Bartlett DL; Smyth MJ; Kershaw MH; Darcy PK
Cancer Res; 2012 Apr; 72(7):1651-60. PubMed ID: 22315352
[TBL] [Abstract][Full Text] [Related]
2. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
[TBL] [Abstract][Full Text] [Related]
4. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment.
Shi W; Siemann DW
Anticancer Res; 2006; 26(5A):3445-53. PubMed ID: 17094465
[TBL] [Abstract][Full Text] [Related]
5. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
6. Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma.
Choi BK; Kim YH; Kim CH; Kim MS; Kim KH; Oh HS; Lee MJ; Lee DK; Vinay DS; Kwon BS
J Immunol; 2010 Aug; 185(3):1404-11. PubMed ID: 20610645
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
8. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation.
Chen SH; Pham-Nguyen KB; Martinet O; Huang Y; Yang W; Thung SN; Chen L; Mittler R; Woo SL
Mol Ther; 2000 Jul; 2(1):39-46. PubMed ID: 10899826
[TBL] [Abstract][Full Text] [Related]
9. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
[TBL] [Abstract][Full Text] [Related]
11. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
12. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
13. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.
Palazón A; Teijeira A; Martínez-Forero I; Hervás-Stubbs S; Roncal C; Peñuelas I; Dubrot J; Morales-Kastresana A; Pérez-Gracia JL; Ochoa MC; Ochoa-Callejero L; Martínez A; Luque A; Dinchuk J; Rouzaut A; Jure-Kunkel M; Melero I
Cancer Res; 2011 Feb; 71(3):801-11. PubMed ID: 21266358
[TBL] [Abstract][Full Text] [Related]
14. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
Cho HM; Rosenblatt JD; Tolba K; Shin SJ; Shin DS; Calfa C; Zhang Y; Shin SU
Cancer Res; 2010 Dec; 70(24):10121-30. PubMed ID: 21159634
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.
Dubrot J; Palazón A; Alfaro C; Azpilikueta A; Ochoa MC; Rouzaut A; Martinez-Forero I; Teijeira A; Berraondo P; Le Bon A; Hervás-Stubbs S; Melero I
Int J Cancer; 2011 Jan; 128(1):105-18. PubMed ID: 20309938
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effects of immune cell-viral biotherapy.
Thorne SH; Negrin RS; Contag CH
Science; 2006 Mar; 311(5768):1780-4. PubMed ID: 16556847
[TBL] [Abstract][Full Text] [Related]
19. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Boozari B; Mundt B; Woller N; Strüver N; Gürlevik E; Schache P; Kloos A; Knocke S; Manns MP; Wirth TC; Kubicka S; Kühnel F
Gut; 2010 Oct; 59(10):1416-26. PubMed ID: 20675696
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
